Anti-acetylcholine receptor antibody titer with extended thymectomy in myasthenia gravis. 1985

K Kagotani, and Y Monden, and K Nakahara, and Y Fujii, and Y Seike, and S Kitamura, and A Masaoka, and Y Kawashima

Twenty-four patients with myasthenia gravis of Osserman's generalized type underwent extended thymectomy through a sternal-splitting approach. Their clinical responses to thymectomy and postoperative changes in anti-acetylcholine receptor antibody titers were evaluated. The follow-up time ranged from 1 month to 7 years and 7 months (average, 36 months). Six patients (25%) had remissions and 17 patients (71%) were improved after operation. The preoperative anti-acetylcholine receptor antibody titers dropped significantly after operation (p less than 0.001). The postoperative reduction in these titers correlated with the time course after operation (p less than 0.05). Their postoperative reduction was significantly greater in the six patients having remissions than in the 15 having marked (p less than 0.02) and the six having moderate improvement (p less than 0.005). This study has revealed that anti-acetylcholine receptor antibody titer in plasma declines progressively after thymectomy, and the postoperative reduction of this titer correlates with the clinical effect of thymectomy.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D011184 Postoperative Period The period following a surgical operation. Period, Postoperative,Periods, Postoperative,Postoperative Periods
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D011950 Receptors, Cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology. ACh Receptor,Acetylcholine Receptor,Acetylcholine Receptors,Cholinergic Receptor,Cholinergic Receptors,Cholinoceptive Sites,Cholinoceptor,Cholinoceptors,Receptors, Acetylcholine,ACh Receptors,Receptors, ACh,Receptor, ACh,Receptor, Acetylcholine,Receptor, Cholinergic,Sites, Cholinoceptive
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K Kagotani, and Y Monden, and K Nakahara, and Y Fujii, and Y Seike, and S Kitamura, and A Masaoka, and Y Kawashima
October 1978, British medical journal,
K Kagotani, and Y Monden, and K Nakahara, and Y Fujii, and Y Seike, and S Kitamura, and A Masaoka, and Y Kawashima
June 1977, British medical journal,
K Kagotani, and Y Monden, and K Nakahara, and Y Fujii, and Y Seike, and S Kitamura, and A Masaoka, and Y Kawashima
June 1995, Acta paediatrica Japonica : Overseas edition,
K Kagotani, and Y Monden, and K Nakahara, and Y Fujii, and Y Seike, and S Kitamura, and A Masaoka, and Y Kawashima
October 1983, Neurology,
K Kagotani, and Y Monden, and K Nakahara, and Y Fujii, and Y Seike, and S Kitamura, and A Masaoka, and Y Kawashima
January 1977, The New England journal of medicine,
K Kagotani, and Y Monden, and K Nakahara, and Y Fujii, and Y Seike, and S Kitamura, and A Masaoka, and Y Kawashima
January 1993, Journal of neurology, neurosurgery, and psychiatry,
K Kagotani, and Y Monden, and K Nakahara, and Y Fujii, and Y Seike, and S Kitamura, and A Masaoka, and Y Kawashima
February 1982, Archives of neurology,
K Kagotani, and Y Monden, and K Nakahara, and Y Fujii, and Y Seike, and S Kitamura, and A Masaoka, and Y Kawashima
February 1988, Journal of autoimmunity,
K Kagotani, and Y Monden, and K Nakahara, and Y Fujii, and Y Seike, and S Kitamura, and A Masaoka, and Y Kawashima
August 2008, Masui. The Japanese journal of anesthesiology,
K Kagotani, and Y Monden, and K Nakahara, and Y Fujii, and Y Seike, and S Kitamura, and A Masaoka, and Y Kawashima
July 2011, Brain and nerve = Shinkei kenkyu no shinpo,
Copied contents to your clipboard!